These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14625884)

  • 1. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.
    Hügle T; Cerny A
    Rev Med Virol; 2003; 13(6):361-71. PubMed ID: 14625884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapies for the treatment of chronic hepatitis C.
    Idéo G; Bellobuono A
    Curr Pharm Des; 2002; 8(11):959-66. PubMed ID: 11945142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental therapy in HCV infection].
    Inglot M; Gładysz A; Rymer W
    Przegl Epidemiol; 2005; 59(2):525-33. PubMed ID: 16190563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease and polymerase inhibitors for the treatment of hepatitis C.
    Asselah T; Benhamou Y; Marcellin P
    Liver Int; 2009 Jan; 29 Suppl 1():57-67. PubMed ID: 19207967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment of patients who do not respond to initial therapy for chronic hepatitis C.
    Shiffman ML
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S13-6. PubMed ID: 15468612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
    Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS; Spooner LM; Belliveau PP
    Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future trends in managing hepatitis C.
    McHutchison JG; Dev AT
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S51-61. PubMed ID: 15081103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymalfasin in the treatment of hepatitis B and C.
    Ciancio A; Rizzetto M
    Ann N Y Acad Sci; 2010 Apr; 1194():141-6. PubMed ID: 20536462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
    Asselah T; Estrabaud E; Bieche I; Lapalus M; De Muynck S; Vidaud M; Saadoun D; Soumelis V; Marcellin P
    Liver Int; 2010 Oct; 30(9):1259-69. PubMed ID: 20633102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
    J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.